Organon & Co | OGN - Debt


Organon & Co reported $8.55B in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Celltrion KRW 160.15B 428.19M Jun/2026
Cspc Pharmaceutical CNY 641.11M 146.11M Dec/2025
Deva Holding AS TRY 5.3B 871.93M Sep/2023
Dianthus Therapeutics USD 1.29M 77K Jun/2026
Divis Laboratories Ltd INR 70M 30M Mar/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Kangmei Pharma CNY 173.71M 42.08M Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 100K 0 Dec/2023
Medical Developments International AUD 1.99M 152K Jun/2025
Merck USD 53.91B 4.79B Jun/2026
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Novartis USD 48.31B 1.31B Sep/2026
Organigram Holdings CAD 31.45M 23.26M Jun/2026
Organon & Co USD 8.55B 1000K Sep/2026
Ovoca Bio EUR 0 0 Jun/2021
Pharma Mar EUR 45.84M 1.7M Jun/2026
Qiagen NV USD 1.64B 2.94M Jun/2026
Sartorius EUR 4.05B 248.8M Jun/2026
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Tilray USD 640.95M 35.17M Jun/2022
Zealand Pharma A/S 414M 8.23M Mar/2026